fb-pixelThe Latest in Financial & Business News - The Boston Globe Skip to main content

More Life Sciences Headlines


Vaccines save lives and generate profits. Why is investment lagging?

Even with the historic effort to develop COVID-19 vaccines, drug makers developing new vaccines for infectious diseases received 3.4 percent of all venture capital raised for biopharma companies in the past 10 years, according to a BIO report.

Gene-editing treatment from Vertex and CRISPR cleared for second rare blood disorder

About five weeks after the Food and Drug Administration greenlighted Casgevy as a breakthrough treatment for sickle cell disease, the agency cleared it for a related condition: transfusion-dependent beta thalassemia.

For-profit biomedical institute, backed by billionaires, launches in Cambridge to speed drug discovery

The institute will be led by cofounder Stuart Schreiber, a Harvard scientist who was also one of the founders of the Broad Institute.

Sage CEO sees encouraging sales for new pill for postpartum depression

The pill, called Zurzuvae, has generated lots of interest among psychiatrists, OB-GYNs, and primary care physicians, the executive said.

Moderna sales were $6.7 billion last year on rising vaccine share

However, the Cambridge-based biotech giant reiterated a downbeat outlook for the year ahead.

Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics

The company, founded in 2019, is developing classes of pills to attack a wide range of diseases.

LabCentral, a crucial incubator for local drug discovery, is slated to grow amid industry slowdown

A more diverse cast of entrepreneurs is only one of the changes underway at the Cambridge nonprofit, which has expanded rapidly amid fluctuating vacancy rates and longer stays by belt-tightening biotech companies.

Alexandria drops South Boston lab project and sells property at deep discount amid biotech’s funk

The real estate investment trust in 2020 bought a self-storage facility and shipping warehouse in South Boston for $168.5 million with plans to develop a life-science campus. The firm this month sold the property again for just $87 million.